Prevention of medication-related osteonecrosis of the jaw: institutional insights from a retrospective study.

IF 1.9 4区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Australian dental journal Pub Date : 2024-12-13 DOI:10.1111/adj.13050

Y S Chang, S Nanayakkara, A Yaacoub, S C Cox

{"title":"Prevention of medication-related osteonecrosis of the jaw: institutional insights from a retrospective study.","authors":"Y S Chang, S Nanayakkara, A Yaacoub, S C Cox","doi":"10.1111/adj.13050","DOIUrl":null,"url":null,"abstract":"Background: Medication-related osteonecrosis of the jaw (MRONJ) is a serious, debilitating condition of the jaw bones. Dental extraction is the most significant independent risk factor for MRONJ. This interim study aimed to evaluate the demographics, medical data and outcomes of patients at risk for MRONJ who underwent dental extractions in a dedicated MRONJ clinic following a risk reduction protocol at a large public dental clinic in New South Wales Health.Methods: A retrospective study analysed demographic and clinical data of patients at risk for MRONJ who underwent dental extractions between March 2020 and April 2024.Results: Data from 329 at-risk patients who underwent 836 dental extractions were included. Most patients were women (75.1%) with a median age of 74 years (IQR 67-80). The primary indication for medications was osteoporosis (85.4%), with Denosumab being the most frequently prescribed (66.9%). Eighteen patients (5.5%) developed MRONJ at 8 weeks of follow-up. Patients categorized as high-risk had a higher incidence of MRONJ (72.2%) compared to the low-risk group (22.2%).Conclusion: This study is the first retrospective audit carried out after implementing preventive protocols in this dedicated MRONJ clinic. The higher incidence of MRONJ in patients classified as 'high risk' underscores the importance of considering individual risk factors in their treatment.","PeriodicalId":8593,"journal":{"name":"Australian dental journal","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian dental journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/adj.13050","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Medication-related osteonecrosis of the jaw (MRONJ) is a serious, debilitating condition of the jaw bones. Dental extraction is the most significant independent risk factor for MRONJ. This interim study aimed to evaluate the demographics, medical data and outcomes of patients at risk for MRONJ who underwent dental extractions in a dedicated MRONJ clinic following a risk reduction protocol at a large public dental clinic in New South Wales Health.

Methods: A retrospective study analysed demographic and clinical data of patients at risk for MRONJ who underwent dental extractions between March 2020 and April 2024.

Results: Data from 329 at-risk patients who underwent 836 dental extractions were included. Most patients were women (75.1%) with a median age of 74 years (IQR 67-80). The primary indication for medications was osteoporosis (85.4%), with Denosumab being the most frequently prescribed (66.9%). Eighteen patients (5.5%) developed MRONJ at 8 weeks of follow-up. Patients categorized as high-risk had a higher incidence of MRONJ (72.2%) compared to the low-risk group (22.2%).

Conclusion: This study is the first retrospective audit carried out after implementing preventive protocols in this dedicated MRONJ clinic. The higher incidence of MRONJ in patients classified as 'high risk' underscores the importance of considering individual risk factors in their treatment.

查看原文本刊更多论文

药物相关颌骨骨坏死的预防：一项回顾性研究的制度见解。

背景：药物相关性颌骨骨坏死（MRONJ）是颌骨的一种严重的衰弱性疾病。拔牙是MRONJ最显著的独立危险因素。这项中期研究旨在评估MRONJ风险患者的人口统计学、医疗数据和结果，这些患者在专门的MRONJ诊所接受拔牙，遵循新南威尔士州一家大型公共牙科诊所的风险降低协议。方法：回顾性研究分析了2020年3月至2024年4月期间接受拔牙的MRONJ风险患者的人口学和临床数据。结果：数据来自329名接受836例拔牙的高危患者。大多数患者为女性（75.1%），中位年龄为74岁（IQR 67-80）。药物治疗的主要适应症是骨质疏松症（85.4%），其中Denosumab是最常用的处方（66.9%）。18名患者（5.5%）在随访8周时出现MRONJ。高危组的MRONJ发生率（72.2%）高于低危组（22.2%）。结论：本研究是在这个专门的MRONJ诊所实施预防性方案后进行的第一次回顾性审核。MRONJ在“高风险”患者中的高发病率强调了在治疗中考虑个体风险因素的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australian dental journal 医学-牙科与口腔外科

CiteScore

4.20

自引率

4.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Australian Dental Journal provides a forum for the exchange of information about new and significant research in dentistry, promoting the discipline of dentistry in Australia and throughout the world. It comprises peer-reviewed research articles as its core material, supplemented by reviews, theoretical articles, special features and commentaries.